Drug promiscuity: problems and promises.
VanDongen, A. M.
Show abstract
Therapeutic drugs exert their effect by binding to a specific target protein (receptor) and altering its activity. However, all drugs have undesirable side effects, which likely result from the drug binding to other protein targets. Drug promiscuity refers to the ability of small molecule compounds to bind with high affinity to multiple proteins. This drug property is responsible for the problems caused by their side effects. But drug promiscuity also presents a promise: if a drug targets numerous proteins, each interaction may contribute to its therapeutic efficacy. The ability to target multiple genes is especially promising for medicines that treat systemic diseases, including neurological disorders and cancers, which result from gene network problems. Here, I will review both aspects of drug promiscuity and illustrate a potential strategy to move this forward using a computer modeling approach.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Deep learning based predictive modeling to screen natural compounds against TNF-alpha for the potential management of Rheumatoid Arthritis: Virtual screening to comprehensive in silico investigation 95%
- Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor 95%
- PharmaNet: Pharmaceutical discovery with deep recurrent neural networks. 94%
Similar papers in this journal
- Multiscale virtual screening optimization for shotgun drug repurposing using the CANDO platform 94%
- Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6 94%
- DeepBindGCN: Integrating Molecular Vector Representation with Graph Convolutional Neural Networks for Accurate Protein-Ligand Interaction Prediction 92%
Similar papers in this journal
- Retro Drug Design: From Target Properties to Molecular Structures 96%
- Streamlining Computational Fragment-Based Drug Discovery through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening 95%
- The use of a graph database is a complementary approach to a classical similarity search for identifying commercially available fragment merges 94%
Similar papers in this journal
- Protein Domain-Based Prediction of Compound-Target Interactions and Experimental Validation on LIM Kinases 95%
- Predicting kinase inhibitors using bioactivity matrix derived informer sets 95%
- Controlling astrocyte-mediated synaptic pruning signals for schizophrenia drug repurposing with Deep Graph Networks 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.